Evidence map›Paper›PMID 38250826›Full record

ArticleVaccines2023

Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.

Christopher W Dukes, Marine Potez, Jeffrey Lancet, Barbara J Kuter, Junmin Whiting, Qianxing Mo, Brett Leav, Haixing Wang, Julie S Vanas, Christopher L Cubitt and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. mRNA vaccines as cancer therapies.Chinese medical journal · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Christopher W DukesDepartment of Immunology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0002-6322-1834
Marine PotezDepartment of Immunology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0001-9083-564X
Jeffrey LancetDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Barbara J KuterDepartment of Infectious Diseases, Moderna, Inc., Cambridge, MA 02139, USA.
Junmin WhitingDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA.
Qianxing MoDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0002-0021-7694
Brett LeavDepartment of Infectious Diseases, Moderna, Inc., Cambridge, MA 02139, USA.
Haixing WangDepartment of Infectious Diseases, Moderna, Inc., Cambridge, MA 02139, USA.
Julie S VanasDepartment of Infectious Diseases, Moderna, Inc., Cambridge, MA 02139, USA.
Christopher L CubittImmune Monitoring Core Facility, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0001-6343-7451
Kimberly Isaacs-SorianoCenter for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL 33612, USA.
Kayoko KennedyCenter for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0009-0000-5741-4915
Julie RathwellCenter for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL 33612, USA.
Julian Diaz CoboDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Wesley O'NanDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Bradley SirakDepartment of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Ning DongDepartment of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Elaine TanJames A. Haley Veterans Hospital, Tampa, FL 33612, USA.
Patrick HwuDepartment of Immunology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Anna R GiulianoCenter for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL 33612, USA.
Shari Pilon-ThomasDepartment of Immunology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Moffitt Cancer Center · USModerna Therapeutics (United States) · USJames A. Haley Veterans' Hospital · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
NCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

Cancer patients are at an increased risk of morbidity and mortality from SARS-CoV-2 infection and have a decreased immune response to vaccination. We conducted a study measuring both the neutralizing and total antibodies in cancer patients following a third dose of the mRNA-1273 COVID-19 vaccine. Immune responses were measured with an enzyme-linked immunosorbent assay (ELISA) and neutralization assays. Kruskal-Wallis tests were used to evaluate the association between patient characteristics and neutralization geometric mean titers (GMTs), and paired

Indexed as

cancer patientCOVID-19hematologic malignancylymphoid cancerneutralizing antibodySARS-CoV-2vaccine

Identifiers

PMID38250826
PMCPMC10818923
OpenAlexW4390111779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.